Premium
Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health‐related quality of life. A prospective cohort study in primary care
Author(s) -
Hajos T. R. S.,
Pouwer F.,
de Grooth R.,
Holleman F.,
Twisk J. W. R.,
Diamant M.,
Snoek F. J.
Publication year - 2011
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2011.03329.x
Subject(s) - medicine , insulin glargine , insulin , diabetes mellitus , type 2 diabetes , quality of life (healthcare) , prospective cohort study , distress , type 1 diabetes , body mass index , cohort , hypoglycemia , endocrinology , clinical psychology , nursing
Diabet. Med. 28, 1096–1102 (2011) Abstract Aims To study prospectively the impact of initiating insulin glargine in suboptimally controlled insulin‐naïve patients with Type 2 diabetes on health‐related quality of life in relation to glycaemic control. Methods Insulin‐naïve Dutch patients with Type 2 diabetes in suboptimal glycaemic control (HbA 1c > 53 mmol/mol; 7%) on maximum dose of oral glucose‐lowering medications were included from 363 primary care practices ( n = 911). Patients started insulin glargine and were followed up for 6 months. At baseline (start insulin therapy), 3 and 6 months, HbA 1c was measured and patients completed self‐report health‐related quality of life measures, including emotional well‐being (World Health Organization‐5 well‐being index), fear of hypoglycaemia (Hypoglycaemia Fear Survey) and diabetes symptom distress (Diabetes Symptom Checklist—revised). Data were analysed using generalized estimating equations analysis. Results HbA 1c (mmol/mol; %) decreased from 69 ± 16; 8.5 ± 1.7 to 60 ± 11; 7.6±1.0 and 57 ± 11; 7.3 ± 1.0 at 3 and 6 months, respectively ( P < 0.001). Pre‐insulin BMI (kg/m 2 ) was 30 ± 5.7, which remained stable at 3 months (30 ± 5.8) and increased to 31 ± 5.9 at 6 months ( P = 0.004); no significant changes in self‐reported symptomatic and severe hypoglycaemia were observed, while nocturnal hypoglycaemia slightly decreased. The Hypoglycaemia Fear Survey score decreased from 14.6 ± 16.2 to 12.1 ± 15.2 and 10.8 ± 14.4 at 3 and 6 months, respectively ( P < 0.001). The Diabetes Symptom Checklist—revised score decreased from 15 ± 14 to 10 ± 12 and 10 ± 13 ( P < 0.001), with most pronounced reductions in hyperglycaemic symptoms and fatigue. The World Health Organization‐5 score increased from 57 ± 25.3 to 65 ± 21.6 at 3‐month follow‐up and 67 ± 21.8 at 6‐month follow‐up ( P < 0.001). Conclusions Results of this observational study demonstrate combined glycaemic and health‐related quality of life benefits of initiating insulin glargine in patients with Type 2 diabetes in routine primary care.